Clinical Trials Logo

Hepatitis, Viral, Human clinical trials

View clinical trials related to Hepatitis, Viral, Human.

Filter by:

NCT ID: NCT00005309 Completed - HIV Infections Clinical Trials

Prospective Study of HIV Infection in Hemophiliacs

Start date: July 1990
Phase:
Study type: Observational

To examine mechanisms of individual differences in the progression of HIV infection in hemophiliacs.

NCT ID: NCT00005306 Completed - Liver Diseases Clinical Trials

Natural History of Post-transfusion Non-A, Non-B Hepatitis

Start date: March 1988
Phase: N/A
Study type: Observational

To compare the clinical, biochemical, and histological status of Non-A, Non-B post-transfusion hepatitis patients with that of patients who did not develop post-transfusion hepatitis.

NCT ID: NCT00005305 Completed - Hemophilia A Clinical Trials

Hepatitis Delta Infections in Hemophiliacs

Start date: September 1987
Phase: N/A
Study type: Observational

To elucidate the role of hepatitis delta virus (HDV) in the development of chronic liver disease in patients with hemophilia.

NCT ID: NCT00005304 Completed - Hemophilia A Clinical Trials

Delta Hepatitis and Liver Disease in Hemophiliacs

Start date: September 1986
Phase:
Study type: Observational

To determine the prevalence of hepatitis delta virus (HDV) in a large cohort of hemophiliacs and to elucidate the role of HDV in the development and progression of liver disease in this population.

NCT ID: NCT00000583 Completed - Hepatitis B Clinical Trials

Hepatitis B Vaccine Clinical Trial

Start date: November 1978
Phase: Phase 3
Study type: Interventional

To determine the efficacy of a hepatitis vaccine in preventing hepatitis B.

NCT ID: NCT00000580 Completed - Hepatitis B Clinical Trials

Interruption of Maternal-to-Infant Transmission of Hepatitis B by Means of Hepatitis B Immune Globulin

Start date: November 1975
Phase: Phase 3
Study type: Interventional

To evaluate whether hepatitis B immune globulin with a high level of antibody against the hepatitis B antigen would be capable of interrupting maternal-fetal transmission of hepatitis B virus, the single most important route of hepatitis spread in the entire Third World.